Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms, Lexicon ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 13.42%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.

In November, Lexicon revealed that the Phase 2b trial completed enrollment. I rated LXRX a “Sell.” The stock has since fallen 68% (even with today’s gains). The following article revisits ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...